Updates in Management of Hypertensive Disorders of Pregnancy

Hypertensive disorders of pregnancy (HDP) were discovered a long time ago but our knowledge about their etiopathogenesis are still limited. These disorders can affect many pregnant women all over the world putting them, their families and their countries under significant health burden. The main goal of all research efforts regarding treatment of HDP is how to prevent highly morbid complications and mortality of HDP that may affect both mother and fetus. Delivery is the main line of treatment for severe cases but we have to put in our mind risk of prematurity as a possible outcome in case of termination besides the possibility of incidence of complications like eclampsia and hypertensive emergency postnatally. Researchers believed that studies working on prevention would result in major improvement of overall women care worldwide, and screening will definitely allow prompt starting therapy for those patients and prevent further sequences. Recently many guidelines support and recommend Aspirin 81 mg for the prevention of preeclampsia in high-risk patients using evidence-based data about the time and indications of its intake. Great efforts have been contributed to developing evidence-based guidelines to enhance our strategies to deal with these disorders. Reviewing, pooling and comparing these guidelines would help us to refine our questions that may need to be answered by further studies. Trials confirmed that application of standardized strategies for treating HDP significantly improves both maternal and fetal outcomes. In this article, we are going to review recent updates and guidelines about the treatment of HDP and provide references for your further readings.

Author(s): Abanoub Gabra and Mariam Gabra

Abstract | Full-Text | PDF

Share This Article